Table 1 Characteristics of Studies Included in the Meta-Analysis
Study Title, Study Design, Author, and Year of Publication | Population and Population Size | Study Design | Mean Monocyte to HDL ratio (MHR) groups | Mortality Outcome | MACEs Evaluated |
|---|---|---|---|---|---|
Monocyte to high-density lipoprotein cholesterol ratio is predictive of in-hospital and five-year mortality in ST-segment elevation myocardial infarction Acikgoz et.al. 2016 [24] | 1598 patients with STEMI who underwent primary PCI from December 2009 to December 2013 | Retrospective Cohort | Tertile 1: 533 patients with 8.63 ± 3.10 Tertile 2: 533 patients with 19.8 ± 3.8 Tertile 3: 532 patients with 30.1 ± 10.5 | • In Hospital Mortality • Long-term mortality (after 60 month follow up) | • In-hospital MACE (Reinfarction, Stroke, Target vessel revascularization, Ventricular arrhythmia, Cardiopulmonary resuscitation and Death) • Long term MACE (Death, stroke, reinfarction and target vessel revascularization during 60-month follow-up) |
Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention Karatas et.al. 2015 [23] | 513 STEMI patients who underwent primary PCI from January 2010 to January 2013 | Retrospective Cohort | Tertile 1: 171 patients with 10.4 Tertile 2: 171 patients with 17.8 Tertile 3: 171 patients with 30.7 | • In-hospital mortality | • In-hospital MACE (Ventricular arrhythmia, Reinfarction, Cardiopulmonary resuscitation, Target vessel revascularization, and Death during index hospitalization) |
The relationship between admission monocyte HDL-C ratio with short-term and long-term mortality among STEMI patients treated with successful primary PCI Cicek et.al. 2016 [25] | 682 patients who underwent primary PCI from March 2013 to September 2015. | Prospective Design | Quartile 1: 172 patients with 8 ± 3 Quartile 2: 169 patients with 14 ± 1 Quartile 3: 161 patients with 19 ± 2 Quartile 4: 180 patients with 28 ± 7 | • In-hospital mortality • Long-term mortality | • In-hospital MACE (Composite of death, nonfatal re-infarction, target vessel revascularization, or new- onset congestive heart failure during hospitalization) • Long Term MACEat 30 month clinical follow-up |